Protara Therapeutics, Inc. (TARA)

USD 5.16

(-8.19%)

Market Cap (In USD)

177.09 Million

Revenue (In USD)

-

Net Income (In USD)

-40.42 Million

Avg. Volume

159.12 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.595-10.48
PE
-
EPS
-
Beta Value
1.786
ISIN
US74365U1079
CUSIP
74365U107
CIK
1359931
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jesse Shefferman
Employee Count
-
Website
https://www.protaratx.com
Ipo Date
2014-10-22
Details
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.